HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its independently developed PD-1/VEGF bispecific...
Hence then, the article about akeso announces the completion of patient enrollment in the phase iii clinical trial harmoni 6 comparing ivonescimab and tislelizumab for first line treatment of sq nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC )
Also on site :
- Amazon's ‘Supportive’ Skechers Wedge Sandals Are ‘Great for Traveling’ and Just $31 Before the Big Spring Sale
- Savannah Guthrie's Mom Nancy Update: Retired K-9 Officer Slams Investigators Not Using Cadaver Dogs—'Defies Logic'
- Physicl stellt auf der NVIDIA GTC die Dateninfrastrukturschicht für Physical AI vor